J. Reginster, The prevalence and burden of arthritis, Rheumatology, vol.41, issue.suppl_1, pp.3-6, 2002.
DOI : 10.1093/rheumatology/41.S1.3

J. Pelletier and J. Martel-pelletier, Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology, Annals of the Rheumatic Diseases, vol.62, issue.90002, pp.79-82, 2003.
DOI : 10.1136/ard.62.suppl_2.ii79

H. Roach, T. Aigner, S. Soder, J. Haag, and H. Welkerling, Pathobiology of Osteoarthritis: Pathomechanisms and Potential Therapeutic Targets, Current Drug Targets, vol.8, issue.2, pp.271-82, 2007.
DOI : 10.2174/138945007779940160

H. Garrigue, J. Maurizis, C. Nicolas, J. Madelmont, D. Godeneche et al., Disposition and metabolism of two acetylcholinesterase reactivators, pyrimidoxime and HI6, in rats submitted to organophosphate poisoning, Xenobiotica, vol.1, issue.7, pp.699-709, 1990.
DOI : 10.1016/S0272-0590(81)80057-7

J. Maurizis, M. Ollier, C. Nicolas, J. Madelmont, H. Garrigue et al., In vitro binding of oxime acetylcholinesterase reactivators to proteoglycans synthesized by cultured chondrocytes and fibroblasts, Biochemical Pharmacology, vol.44, issue.10, pp.1927-1960, 1992.
DOI : 10.1016/0006-2952(92)90094-Y

H. Shindo, E. Nakajima, N. Miyakoshi, and E. Shigehara, Autoradiographic studies on the distribution of quaternary ammonium compounds. III. Distribution, excretion and metabolism of 14C-labeled pancuronium bromide in rats., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.22, issue.11, pp.2502-2512, 1974.
DOI : 10.1248/cpb.22.2502

C. Nicolas, M. Borel, J. Maurizis, N. Gallais, M. Rapp et al., Synthesis ofN-quaternary ammonium [3H] and [99mTc]polyazamacrocycles, potential radiotracers for cartilage imaging, Journal of Labelled Compounds and Radiopharmaceuticals, vol.43, issue.6, pp.585-94, 2000.
DOI : 10.1002/(SICI)1099-1344(200005)43:6<585::AID-JLCR343>3.0.CO;2-H

J. Madelmont, I. Giraud, C. Nicolas, J. Maurizis, M. Rapp et al., Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use for treatment or diagnosis of pathologies affecting cartilage, 2001.

J. Maurizis, M. Rapp, C. Nicolas, M. Ollier, M. Verny et al., Disposition in rats of N-pyridinium-propyl-cyclam, N-triethylammoniumpropyl-cyclam , and N-[Triethylammonium]-3-propyl-[15]ane-N5, potential cartilage imaging agents, Drug Metab Dispos, vol.28, pp.418-440, 2000.

C. Nicolas, M. Verny, I. Giraud, M. Ollier, M. Rapp et al., New Quaternary Ammonium Oxicam Derivatives Targeted toward Cartilage:?? Synthesis, Pharmacokinetic Studies, and Antiinflammatory Potency, Journal of Medicinal Chemistry, vol.42, issue.25, pp.5235-5275, 1999.
DOI : 10.1021/jm991120o

M. Ollier, J. Maurizis, C. Nicolas, J. Bonafous, M. De-latour et al., Joint scintigraphy in rabbits with 99mtc-N-[3-(triethylammonio)propyl]- 15ane-N5, a new radiodiagnostic agent for articular cartilage imaging, J Nucl Med, vol.42, pp.141-146, 2001.

E. Miot-noirault, A. Vidal, P. Auzeloux, J. Madelmont, J. Maublant et al., First In Vivo SPECT imaging of Mouse Femorotibial Cartilage using 99mTc-NTP 15-5, Mol Imaging, vol.7, pp.263-71, 2008.
URL : https://hal.archives-ouvertes.fr/hal-01505259

E. Miot-noirault, A. Vidal, P. Pastoureau, J. Bonafous, A. Chomel et al., Early detection and monitoring of cartilage alteration in the experimental meniscectomised guinea pig model of osteoarthritis by 99mTc-NTP 15-5 scintigraphy, European Journal of Nuclear Medicine and Molecular Imaging, vol.42, issue.Suppl A, pp.1280-90, 2007.
DOI : 10.1007/s00259-006-0320-2

P. Pastoureau, S. Leduc, A. Chomel, D. Ceuninck, and F. , Quantitative assessment of articular cartilage and subchondral bone histology in the meniscectomized guinea pig model of osteoarthritis, Osteoarthritis and Cartilage, vol.11, issue.6, pp.412-435, 2003.
DOI : 10.1016/S1063-4584(03)00050-5

M. Adams, J. Matyas, D. Huang, and G. Dourado, Expression of proteoglycans and collagen in the hypertrophic phase of experimental osteoarthritis, J Rheumatol, vol.43, pp.94-101, 1995.

L. Sandell and T. Aigner, Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis, Arthritis Research, vol.3, issue.2, pp.107-120, 2001.
DOI : 10.1186/ar148

R. Marco, S. Gitelis, G. Brebach, and J. Healey, Cartilage Tumors: Evaluation and Treatment, Journal of the American Academy of Orthopaedic Surgeons, vol.8, issue.5, pp.292-304, 2000.
DOI : 10.5435/00124635-200009000-00003

E. Miot-noirault, F. Gouin, A. Vidal, M. Rapp, J. Maublant et al., First Preclinical Imaging of Primary Cartilage Neoplasm and Its Local Recurrence Using 99mTc-NTP 15-5 Radiotracer, Journal of Nuclear Medicine, vol.50, issue.9, 2009.
DOI : 10.2967/jnumed.108.056721

A. Nguyen, T. Akhurst, S. Larson, D. Coit, and M. Brady, PET Scanning with 18F 2-Fluoro-2-Deoxy-?-Glucose (FDG) in Patients with Melanoma Benefits and Limitations, Clinical Positron Imaging, vol.2, issue.2, pp.93-101, 1999.
DOI : 10.1016/S1095-0397(99)00006-0

A. Siccardi, Tumor immunoscintigraphy by means of radiolabeled monoclonal antibodies: multicenter studies of the Italian National Research Council Special Project ''Biomedical Engineering, Cancer Res, vol.1, pp.899-903, 1990.

P. Blower, D. Costa, D. Lane, D. Lui, R. Brown et al., Early detection of melanoma metastases with radioiodinated methylene blue

T. Salopek, J. Scott, A. Joshua, M. Smylie, J. Logus et al., Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9): a new potential melanoma imaging agent, European Journal of Nuclear Medicine, vol.28, issue.4, pp.408-425, 2001.
DOI : 10.1007/s002590000455

M. Moreau, D. Parry, J. Michelot, P. Labarre, J. Madelmont et al., Synthèse, étude chez le rat, de composés radioiodés utilisables pour l'exploration du système nerveux central, Eur J Med Chem, vol.21, pp.423-454, 1986.

J. Michelot, M. Moreau, P. Labarre, J. Madelmont, A. Veyre et al., Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma, J Nucl Med, vol.32, pp.1573-80, 1991.

M. Moreau, J. Michelot, J. Papon, M. Bayle, P. Labarre et al., Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-Diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents, Nuclear Medicine and Biology, vol.22, issue.6, pp.737-784, 1995.
DOI : 10.1016/0969-8051(95)00020-X

M. Moreau, J. Michelot, A. Veyre, J. Madelmont, D. Godeneche et al., Agents pour le diagnostic et le traitement des mélanomes, dérivés halogénés utilisables comme de tels agents et leur préparation, 1990.

M. Moreau, J. Michelot, A. Veyre, J. Madelmont, D. Godeneche et al., Agents for diagnosing and treating melanomas, aromatic halogenated derivatives usable as such agents and their preparation, 1990.

W. Brandau, T. Niehoff, P. Pulawski, J. M. Dutschka, K. Sciuk et al., Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma, J Nucl Med, vol.37, pp.1865-71, 1996.

C. Nicholl, A. Mohammed, W. Hull, B. Bubeck, and M. Eisenhut, Pharmacokinetics of iodine-123-IMBA for melanoma imaging, J Nucl Med, vol.38, pp.127-160, 1997.

R. Larisch, K. Schulte, H. Vosberg, T. Ruzicka, and H. Müller-gärtner, Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo, J Nucl Med, vol.39, pp.996-1001, 1998.

W. Brenner, H. Klomp, K. Bohuslavizki, B. Szonn, W. Kampen et al., Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy- N -[(1-ethyl-2-pyrrolidinyl)methyl]benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.26, issue.12, pp.1567-71, 1999.
DOI : 10.1007/s002590050496

P. Labarre, J. Papon, M. Moreau, N. Moins, M. Bayle et al., Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent, Melanoma Research, vol.12, issue.2, pp.115-136, 2002.
DOI : 10.1097/00008390-200204000-00003

C. John, W. Bowen, T. Saga, S. Kinuya, B. Vilner et al., A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)-4- iodobenzamide, J Nucl Med, vol.34, pp.2169-75, 1993.

T. Pham, I. Greguric, X. Liu, P. Berghofer, P. Ballantyne et al., Synthesis and Evaluation of Novel Radioiodinated Benzamides for Malignant Melanoma, Journal of Medicinal Chemistry, vol.50, issue.15, pp.3561-72, 2007.
DOI : 10.1021/jm0701627

S. Mansard, J. Papon, M. Moreau, E. Miot-noirault, P. Labarre et al., Uptake in melanoma cells of N-(2-diethylaminoethyl)-2-iodobenzamide (BZA2), an imaging agent for melanoma staging: relation to pigmentation, Nuclear Medicine and Biology, vol.32, issue.5, pp.451-459, 2005.
DOI : 10.1016/j.nucmedbio.2005.04.006

F. Chehade, C. De-labriolle-vaylet, N. Moins, M. Moreau, J. Papon et al., Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I- BZA and (14)C-I-BZA, J Nucl Med, vol.46, pp.1701-1707, 2005.

J. Guerquin-kern, F. Hillion, J. Madelmont, P. Labarre, J. Papon et al., Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences, Biomed Eng online, vol.6, p.10, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00112916

J. Michelot, M. Moreau, A. Veyre, J. Bonafous, F. Bacin et al., Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide), J Nucl Med, vol.34, pp.1260-1266, 1993.

N. Moins, D. Incan, M. Bonafous, J. Bacin, F. Labarre et al., 123 I- N -(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.11, pp.1478-84, 2002.
DOI : 10.1007/s00259-002-0971-6

N. Moins, J. Papon, H. Seguin, D. Gardette, M. Moreau et al., Synthesis, characterization and comparative biodistribution study of a new series of p -Iodine-125 benzamides as potential melanoma imaging agents, Nuclear Medicine and Biology, vol.28, issue.7, pp.799-808, 2001.
DOI : 10.1016/S0969-8051(01)00242-6

J. Madelmont, J. Chezal, N. Moins, J. Teulade, and O. Chavignon, Labelled analogues of halobenzamides as radiophamraceuticals, 2008.

J. Chezal, J. Papon, P. Labarre, C. Lartigue, M. Galmier et al., -(2-diethylaminoethyl)-4-iodobenzamide for Imaging and Targeted Radionuclide Therapy of Melanoma, Journal of Medicinal Chemistry, vol.51, issue.11, pp.3133-3177, 2008.
DOI : 10.1021/jm701424g

M. Bonnet-duquennoy, J. Papon, F. Mishelanny, P. Labarre, M. Gardette et al., Chezal Jm, Moins N. [131I]ICF01012, a potential agent for targeted radionuclide therapy of melanoma, Abstracts World Molecular Imaging Congress, pp.8-810, 2008.

P. Labarre, J. Papon, A. Rose, J. Guerquin-kern, L. Morandeau et al., Melanoma affinity in mice and immunosuppressed sheep of [(125)I]N-(4-dipropylaminobutyl)-4-iodobenzamide, a new targeting agent, Nucl Med Biol, vol.99, pp.783-91, 2008.